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Abstract 
Background: Mammogram screening for surveillance and detection of breast cancer has long 
been recognized as a preventative health measure in primary care for women. However, easily 
recognizing when to screen individual women, based on age and risk factors, lacks clear 
guidance and often ends in fragmented and inconsistent practices among providers.  
Methods: By developing and implementing the Screening Mammogram Initiation Protocol 
(SMIP), the desired goals of this project were to: a) align breast cancer screening  
recommendations to better meet individualized patient needs in primary care utilizing best 
practice guidelines, b) increase the rate of breast cancer screening across various demographics, 
and c) create a standardized screening protocol tool that increases shared decision making based 
on individual risk factors. Outcome measures were reflected by an increase in provider 
knowledge towards female breast health counseling, an increase in rates of breast cancer 
screening discussions, and the successful implementation of the SMIP at a local primary care 
clinic in Oakland, California.  
Results: Responses from the pre/post knowledge and post-implementation surveys showed 
improved provider understanding of the current breast cancer screening guidelines for average 
and high-risk females as well as 90% satisfaction utilizing the SMIP in practice. Electronic data 
collection after nine-weeks showed an eight percent increase (64% to 72%) in referrals for 
women aged 40-49 eligible for breast cancer screening and seven percent increase (73% to 80%) 
in referrals for women aged 50-59 eligible for breast cancer screening.  
Conclusion: This evidence-based change in practice project ultimately improved the quality of 
care by enhancing preventative health delivery, contribute to increased screening, and likely 
impact breast cancer morbidity, and mortality rates. 
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Section II: Introduction 
Problem Description  
 In the United States, breast cancer continues to be the second most common cancer 
diagnosis in females, and the second leading cause of cancer death in women (ACS, 2019; 
Centers for Disease Control and Prevention [CDC], 2018). It is estimated, that in 2019, 268,600 
new diagnoses of breast cancer will occur, and 10% of those new cases will be found in women 
under the age of 45 (ACS, 2019; CDC, 2018; Surveillance, Epidemiology, and End Results 
Program [SEER], n.d.). Of women under 45, breast cancer is most commonly found in the 
African American race who also experience the overall highest death rate associated with breast 
cancer in comparison to White, Asian, Pacific Islander, Native American, Hispanic, and Non-
Hispanic women (Breastcancer.org, 2019; SEER, n.d.). Women with a first-degree relative 
(mother, sister, daughter) with history of breast cancer have a near two-fold increased risk of 
developing breast cancer (Breastcancer.org, 2019). The lifetime breast cancer risk for women 
who have a BRCA1 or BRCA2 gene mutation is 72% and 69%, respectively and is more 
prevalent in the younger population (Breastcancer.org, 2019). One in eight women will develop 
breast cancer in their lifetime, 15% will have an associated first-degree relative, and 5-10% will 
be related to a genetic mutation (ACS, 2019; Breastcancer.org, 2019).  
Overview of the Current Guidelines 
The recommendations for initiating breast cancer screening (BCS) with a mammogram, 
the frequency with which to continue monitoring, and the screening discontinuation age differ 
among reputable organizations and professional societies (Table 1).  
Table 1: 
Breast Cancer Screening Guidelines  
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Group Age to Initiate 
Mammograms 






No later than 50  





initiating the BCS 
screening process to start 
at age 40. The age to 
begin mammography 
requires an informed 
decision based on 
provider-patient 
discussion about the 
potential risks, benefits, 
and patient 
values/preferences. 
ACR2 40 1 Life expectancy 




of imaging results 
Screening considerations 
should include educating 
women of the risks, 
benefits, and limitations 
of screening to help the 


























interpreted as the health 
care professional will 
provide education on the 
different options and help 
the patient consider their 
values/preferences to make 
an informed decision. 
NCCN4 40 1 Limited life 








women on the potential 
risks, benefits, limitations 
of mammography, and 
consider the patient’s 
values/preferences. 
Annual screening offers 
the opportunity for 
updating BC risk 
assessments, modifiable 
risk reduction 
counseling, review of 
red-flag symptoms, and 
option for clinical breast 
exams.  















Grade C implies women 
can choose the option to 
initiate screening between 
ages 40-49 years if they 
value the potential benefits 
of BCS mammography 
greater than the potential 
risks. 
Adapted from:  
1. American College of Obstetrics and Gynecologists (ACOG) 
The American College of Obstetricians and Gynecologists. (2017). ACOG practice bulletin: Clinical management 




2. American College of Radiology (ACR) 
Lee, C. H., Dershaw, D. D., Kopans, D., Evans, P., Monsees, B., Monticciolo, D., … Burhenne, L. W. (2010). 
Breast cancer screening with imaging: Recommendations from the society of breast imaging and the ACR on the use 
of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast 
cancer. Journal of the American College of Radiology, 7(1), 18-27. doi:10.1016/j.jacr.2009.09.022 
 
Monticciolo, D. L., Newell, M. S., Hendrick, R. E., Helvie, M. A., Moy, L., Monsees, B., . . . Sickles, E. A. (2017). 
Breast cancer screening for average-risk women: Recommendations from the ACR commission on breast 
imaging. Journal of the American College of Radiology, 14(9), 1137-1143. doi:10.1016/j.jacr.2017.06.001 
 
3. American Cancer Society (ACS)  
Oeffinger, K. C., Fontham, E. T. H., Etzioni, R., Herzig, A., Michaelson, J. S., Shih, Y. T., . . . Wender, R. (2015). 
Breast cancer screening for women at average risk: 2015 guideline update from the American cancer 
society. Jama, 314(15), 1599-1614. doi:10.1001/jama.2015.12783 
 
4. National Comprehensive Cancer Network (NCCN) 
Bevers, T. B., Helvie, M., Bonaccio, E., Calhoun, K. E., Daly, M. B., Farrar, W. B., . . . Kumar, R. (2018). Breast 
cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology. Journal of the 
National Comprehensive Cancer Network : JNCCN, 16(11), 1362-1389. doi:10.6004/jnccn.2018.0083 
 
5. United States Preventive Services Task Force (USPSTF)  
Siu, A. L. (2016). Screening for breast cancer: U.S. preventive services task force recommendation 
statement. Annals of Internal Medicine, 164(4), 279. doi:10.7326/M15-2886 
 
The United States Preventive Services Task Force (USPSTF) currently recommends 
biennial mammograms for females starting at age 50 and continuing until age 74 (Siu, 2016). For 
women ages 40 to 49, the USPSTF recommends selective screening based on individual factors, 
given a lower net benefit of avoided breast cancer deaths versus harm (Nelson et al., 2016a; Sui, 
2016). In this case, harm is defined as overdiagnosis and overtreatment. However, it is difficult 
to quantify if evaluation and treatment of the diagnosed breast cancer found on imaging would 
“become a threat to a woman’s health, or even apparent, during her lifetime” (Siu, 2016, p.280, 
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para 2). The USPSTF proposes these guidelines based using a meta-analysis using absolute rates 
that out of every 10,000 women aged 40-49 screened, there would be three fewer breast cancer 
deaths, in comparison to eight fewer deaths for women aged 50-59, and 21 fewer deaths in 
women aged 60-69 who had routine screening (Nelson et al., 2016a). This data implies younger 
women completing routine mammograms experience less breast cancer related deaths than older 
women, which would be expected since the incidence averages of breast cancer diagnosis and 
death in the United States are ages 62 and 68 (SEER, n.d.). The USPSTF’s analysis of BCS 
effectiveness regards breast cancer mortality reduction as the primary positive outcome across all 
ages, as all-cause mortality was not found statistically significant, and the incidence of advanced 
breast cancer diagnosis based on screening was only found reduced for women ages 50 or older, 
but not for women ages 39-49 (Nelson et al., 2016a).  
The USPSTF categorizes women who are considered average risk as those without 
personal or familial breast cancer history, without known BRCA1 or BRCA2 gene mutation, and 
without a history of radiation therapy to the chest at a young age (Sui, 2016). The USPSTF 
recognizes women with familial breast cancer history or possible genetic BRCA1 or BRCA 2 
mutations at higher risk of developing breast cancer and may benefit from initiating screening 
earlier than 50 years (Nelson et al., 2016a; Sui, 2016). The USPSTF has a “B” recommendation 
for screening women for BRCA mutations and referral for genetic counseling should occur 
starting at age 18 and re-assessed “periodically” (Moyer, 2014, p. 274, para 2). However, no 
further recommendations addressing the frequency of BRCA mutation screening is offered. 
Screening recommendations for potentially high-risk women include those with familial 
members with “breast, ovarian, tubal, or peritoneal cancer,” in addition to a positive screening 
result from one screening risk model (FHS-7, Manchester Scoring System, Ontario Family 
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History Assessment, Pedigree Assessment Tool, Referral Screening Tool) (Moyer, 2014, p. 271, 
para 4). Females with risk factors or whom may experience significant familial medical history 
changes over time may miss opportunities of being identified for early detection screening 
without concrete recommendations.  
In contrast, the National Comprehensive Cancer Network (NCCN) and American College 
of Radiology (ACR) recommend annual mammogram screening to start at age 40 with 
discontinuation dependent upon limited life expectancy (from factors such as co-morbidities, 
age) determined by provider discretion and if no further interventions (i.e. additional imaging, 
biopsies, breast cancer treatment) were to be pursued regardless of mammogram imaging results 
(Bevers et al., 2018; Lee et al., 2010; Monticciolo et al., 2017).  
American College of Obstetrics and Gynecologists (ACOG) (2017) advises women 
should be counseled on BCS and be offered the choice to start mammograms at age 40 (but no 
later than age 50) determined through a shared-decision between the patient and provider. 
American Cancer Society (ACS) recommends annual screening mammogram starting at age 45 
until age 54 (with individually tailored screening between the ages of 40-44), then every one to 
two years starting at age 55 onwards, until life expectancy is less than 10 years (Oeffinger et al., 
2015).  
The NCCN and ACR advocate for annual screening starting at age 40 because this age 
group has the largest potential to experience the benefits of breast cancer mortality reduction, 
improved survival rates, and better breast cancer treatment options (Bevers et al., 2018; Lee et 
al., 2010). Per the ACS (2017a), estimated breast cancer death rates for women ages 40-49 were 
9%, 19% for women ages 50-59, 23% for women ages 60-69, 20% for women ages 70-79, and 
the highest occurrence of 27% in women aged 80 and above. The ACS’s recommendation to 
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start mammograms at age 45 is based on quality evidence ratings found in their conducted 
systematic review evaluating the harms and benefits of BCS in 5-year intervals (Oeffinger et al., 
2015). ACS advocates for introducing the discussion for BCS at age 40 to identify women at 
higher risk that would benefit from mammography earlier than age 45 (Oeffinger et al., 2015).  
ACOG (2017) endorses counseling for BCS starting at age 40, with the option to start 
mammography because evidence from the ACS and USPSTF reviews found women receiving 
mammograms between ages 40-49 experience quantifiable breast cancer mortality reduction 
(Nelson et al., 2016a; Oeffinger et al., 2015). ACOG (2017) also supports a patient’s decision to 
defer beginning mammograms until age 50, because determining an appropriate balance between 
harm versus benefit is subjective and should incorporate the patient’s priorities and beliefs. 
Overall these guidelines propose patient involvement through a shared decision making 
approach, suggesting that BCS may not fit a standardized “one size fits all” approach.   
There is general consensus amongst ACOG, ACR, ACS, and NCCN that women with 
average risk of developing breast cancer are those without personal or familial breast/ovarian 
cancer history, genetic predisposition for suspected or known gene mutations, or have a history 
of ionizing radiation exposure to the chest at a young age (10-30 years) (ACOG, 2017; ACS, 
2017a; Bevers et al., 2018; Daly et al., 2017; Lee et al., 2010). Depending on the risk factor, 
women may benefit from earlier screening mammograms, additional imaging modalities, and 
genetic counseling. Identifying and following women who may not have initial risk factors, but 
develop them over time should be a part of a routine assessment, and re-evaluated regularly for 
best management of comprehensive BCS practices. Other breast cancer risk factors identified 
among these organizations include dense breast tissue, history of DCIS or LCIS, benign breast 
disorders, women of Ashkenazi Jewish decent, nulliparity or first pregnancy after age 35, early 
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menarche (age 11 or younger), late menopause (after 55 years), never having breastfed, post-
menopausal combination hormone therapy, and post-menopausal high bone mineral density 
(ACOG, 2017; ACS, 2017a; Lee et al., 2010). Environmental and behavioral influences 
contributing to breast cancer include alcohol consumption, tobacco smoking, obesity, 
diethylstilbestrol exposure, and working night shifts (ACOG, 2017; ACS, 2017a). 
The lack of uniform BCS guidelines or a standardized decision toolkit for when to 
implement screening has caused inconsistent practices in primary care, potentially affecting 
outcomes for all women, including those at average or high risk. This difference in clinical 
practice ultimately impacts the opportunity to optimally screen and re-screen women for breast 
cancer in early detection, secondary, or tertiary care. 
Current Practice and Insurance Coverage  
 Initiatives C-17 and C-18.1 from Healthy People 2020 aims for a 10% improvement in 
the proportion of women ages 50-74 who receive BCS (target of 81.1%), and are counseled by 
their providers about mammograms (target of 76.8%) (Office of Disease Prevention and Health 
Promotion, 2018a). Data from the 2015 National Health Interview Survey indicates that only 
71.6% of females aged 50-74 years in the United States receive BCS, and only 66.7% are 
counseled by their providers about screening mammograms (Office of Disease Prevention and 
Health Promotion, 2018a). The suboptimal screening rate shows a large percentage of the female 
population was not offered screening for early detection, which can be a life-saving preventative 
service. Conflict in recommendations among the ACOG, ACR, ACS, NCCN, and the USPSTF 
regarding screening women under the age of 50, suggests there is a greater gap of missed 
opportunities for providers to offer high-quality, comprehensive care to their patients.  
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Radhakrishnan et al. (2017) conducted a national survey of primary care providers about 
their BCS practices, and found that physicians primarily trusted BCS recommendations from 
ACS, ACOG, and USPSTF. Each of these guidelines endorses different initial screening ages, 
ongoing screening frequency, and age at which to discontinue mammography. In this study, 81% 
of physicians reported offering BCS mammography to women aged 40-44, 88% to women aged 
45-49, and 67% offered mammography to women 75 or older (Radhakrishnan et al., 2017). 
These varying practices among providers represent the lack of a clear algorithm or screening 
process that incorporates all the best evidence-based recommendations to provide high quality 
care for optimal breast health. Furthermore, rescreening guideline practices fluctuate from 
annually to biennially between organizations and for the ACS, the frequency changes from one 
to two years after age 55. Radiology reports of the testing agencies performing the mammograms 
often follow the ACR guidelines, which offers recommendation for annual screening for women 
of all ages. In some cases, patients may be elicited back for routine annual follow-up by the 
testing agency, which may directly conflict with the chosen practice guidelines of the primary 
care institution. This implicates a potential for further confusion among primary care clinics 
selecting a standard institutional recommendation to follow, as well as lack of clarity for 
providers in navigating appropriate care for each female patient.  
 The current BCS practice that is most widely used, is the USPSTF guideline. The Centers 
for Medicare and Medicaid Services (CMS) utilize the recommendations to establish the 
standard protocol and evaluate core measures of quality health outcomes (Kaiser Family 
Foundation, 2018). To date, Medicare Part B completely covers annual mammography screening 
starting at 40, however, Medicaid BCS coverage is dependent on the Affordable Care Act (ACA) 
criteria for that state (Kaiser Family Foundation, 2018). Many private and individual insurance 
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plans fall under the ACA provisions that utilize the USPSTF’s grade “A or B” and Health 
Resources and Services Administration (HRSA) practice recommendations (Kaiser Family 
Foundation, 2018). The USPSTF grade “C” recommendation (stance originally published in 
2009 and again in 2016) to selectively offer certain women to undergo mammography ages 40-
49, reflected in 2009 that not all health insurances were required to provide full insurance 
coverage consequently creating a barrier of accessibility to screen for women in this age range 
(Sui, 2016). In attempt to reduce this health disparity, in 2012 the Department of Health and 
Human Services (DHHS) implemented a provision requiring the ACA to use the 2002 USPSTF 
recommendations for BCS that entail a women can receive mammography starting at age 40 
every one to two years with or without clinical breast exams (National Women’s Law Center, 
2013). This provision remains enacted due to the passing of the Comprehensive Omnibus 
Funding law in 2015 (Sui, 2016). HRSA (2018) also updated its recommendation guidelines in 
2016 founded upon the Women’s Preventive Services Initiative (organized by ACOG) and 
follow the same ACOG proposals. BCS is a preventative health service that should be offered to 
any women seeking this care. Lack of insurance coverage or potential costs associated should not 
interfere with universal preventative screens or prohibit a women’s access to BCS services.    
 Epidemiology. Worldwide, breast cancer is the most common cancer in females for both 
the developed and underdeveloped countries (World Health Organization [WHO], 2018). With 
estimates of 508,000 deaths due to breast cancer in 2011, 50% of cases and 42% of those deaths 
occurred in developed countries. In the North and South Americas, there is a 25.2% incidence of 
breast cancer in women of all ages and a 15.1% occurrence of death related to breast cancer 
(Global Cancer Observatory, 2018). By 2030, it is projected in the North and South Americas 
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there will be an additional 572,000 new breast cancer cases and 130,000 deaths with the United 
States leading in breast cancer incidence (Global Cancer Observatory, 2018).  
In 2015, the United States Cancer Statistics Working Group (2018) reported there were a 
total of 242,476 females diagnosed with breast cancer. Of those diagnosed (Table 2), Caucasian 
women experience the highest incidence of new breast cancer diagnosis, secondary to African 
Americans, followed by Asians, Hispanics, and Native American women. While this data 
captures the diagnosed rates, it is unclear whether the lack of screening contributes to these lower 
rates among the minority population. This data also captures the age-specific rates of new breast 
cancer diagnosis from 40-79 years (Table 3). This information reflects a clear escalation in the 
quantity of women diagnosed with breast cancer as one ages. It is noteworthy that women aged 
75-79 experience the second highest rate of new breast cancer diagnosis, but it is an ‘I’ 
(insufficient) recommendation by the USPSTF due to the lack of high-level evidence (United 
States Preventative Services Task Force, 2019).  




Number of Females 
Diagnosed with 




Asian/Pacific Islander 94.3 
Hispanic 93.6 
American Indian/Alaskan Native 71.2 
United States Cancer Statistics Working Group. (2018). United States cancer statistics: Data  
visualizations. Retrieved from https://gis.cdc.gov/Cancer/USCS/DataViz.html 
 
Table 3: 2018 Reported Age Specific Rates of New Breast Cancer Diagnosis  
 
Age Number of Females 
with New Breast 
Cancer Diagnosis 
per 100,000 









United States Cancer Statistics Working Group. (2018). United States cancer statistics: Data  
visualizations. Retrieved from https://gis.cdc.gov/Cancer/USCS/DataViz.html 
 
California’s leading cancer diagnosis is female breast cancer (NBCCEDP, 2013). At age 
45-65, there is a 1:21 ratio for the probability of female breast cancer diagnosis in California, and 
1:14 chance between ages 65-85 (American Cancer Society, 2013). Surveillance mammograms 
have been identified as an effective screening tool for identifying breast cancer and when done 
before an individual becomes symptomatic, early stage diagnosis and successful treatment with 
cure is higher. If breast cancer is found to be localized at the time of diagnosis, the five-year 
survival rate is 100% (American Cancer Society, 2013).  
Setting 
The Federally Qualified Health Center (FQHC) chosen for this doctoral project provides 
care to women that are American Indians, Alaskan Natives, Black, Asian, Hispanics, and Non-
Hispanics of the surrounding Bay Area (Oakland, Alameda, Richmond, and San Francisco). The 
FQHC in Oakland primarily works with members that lack healthcare coverage, are underserved, 
and have low socioeconomic status. Disparity factors of educational level, income, occupation, 
and environmental exposures predispose and contribute to the risk of development of illness, 
disease, and breast cancer (Office of Disease Prevention and Health Promotion, 2018a). The 
opportunity to improve BCS coverage for all female members and possibly impact health 
outcomes compelled the author to collaborate and conduct the project at this clinical site.  
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From September 2017 to 2018, the race of women at FQHC aged 50-74 years that were 
eligible for BCS (836 total) were identified (Table 4) as African American women as the highest 
secondary to Latino or Hispanic women, followed by American Indian/Alaskan Native, 
Caucasian, Asian, declined to specify/other/unknown, Native American, Native Hawaiian or 
Pacific Islander, and Middle Eastern or North African. Of this population, compliance rates in 
alignment with FQHC’s current standards that utilizes the UPSPSTF’s guidelines show Native 
Hawaiian or Other Pacific Islander women with the highest mammogram completions and Asian 
women with the lowest. Of the nine patient identified races, only Native Hawaiian or Other 
Pacific Islander women currently meet Healthy People 2020’s C-17 objective target of an 81.1% 
rate of receiving BCS (Office of Disease Prevention and Health Promotion, 2018a). The varying 
rates of mammogram screening completions reflects an under performance in secondary 
preventative care despite FQHC’s current system of screening. This reveals an opportunity for 
improvement and understanding of how certain races have higher rates of mammography 
completion and the barriers preventing those with lower percentages.  
Table 4: Mammogram Screening Rates Based on FQHC’s Current Breast Cancer Screening 
Guidelines (USPSTF: Biennial Screening for females ages 50-75) 
 
Patient Identified Race  Eligible  
(Total: 836) 
Did Not Receive 
Mammogram (Total: 237) 
Compliance 
Rate  
Native Hawaiian or Other Pacific 
Islander 
30 3 90% 
Latino or Hispanic 213 46 78.4% 
Declined to 
specify/Other/Unknown 
39 9 76.9% 
Native American-Multi-Race 38 10 73.6% 
Black or African American 271 75 72.3% 
Middle Eastern or North African 18 6 66.6% 
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White 80 29 63.7% 
American Indian/Alaskan Native 85 32 62.3% 
Asian 41 21 48.7% 
I2I Tracking search conducted for 9/10/17-9/10/2018 
 
In Alameda County, the 2014 reported annual percentage of female breast cancer cases 
diagnosed at an early stage (localized or in situ) are 76.9% for Non-Hispanic White, 65.9% for 
African American, 70.4% for Hispanic, and 75.9% for Asian/Pacific Islander females 
respectively (ACS, 2017b). The actual rates in percent are not available for the following 
populations: American Indian and Alaskan Native females. However, the Office of Disease 
Prevention and Health Promotion (ODPHP) suggest that about 53.1% of American Indians and 
Alaska Natives females are screened with mammograms (Office of Disease Prevention and 
Health Promotion, 2018c). This is 21.4% lower than the highest group of African American 
women receiving breast cancer mammography within the last two years (Office of Disease 
Prevention and Health Promotion, 2018c). Lower screening rates among this population reflect a 
higher risk for missed routine care and preventative health services. With less access to 
comprehensive care, these vulnerable populations will consequently suffer larger health 
disparities.  
Available Knowledge  
 Given all the various guidelines, there remains confusion among providers, about which 
guideline is best and when to actually start screening. There is considerable debate about the 
risks of mammography screening causing ‘harm’ to women in their 40s that could lead to 
increased false-positives requiring additional imaging, the risk of radiation induced breast cancer 
from the cumulation of mammography, the potential for overdiagnosis, and additional 
STANDARDIZING MAMMOGRAM SCREENING 20 
psychological stress (Nelson et al., 2016b). The PICOT questions asked to further understand the 
current evidence, gaps, and risks of age-based routine breast screening are as follows:  
1) Do guidelines (C) for starting BCS (O) in females (P) vary by age (T) for routine 
screening mammograms (I)?  
2) Do the contrasting (C) screening guidelines (I) affect outcomes for breast cancer 
identification (O) in females (P) aged 40-49 (T)?  
3) What are the advantages (O) and disadvantages (C) of starting screening early versus late 
(I), for women aged 40-49 (P)?  
4) What are the risk factors (I) predisposing women (P) towards developing breast cancer 
(O) earlier than the general population (C)?   
A systematic literature search was conducted in October 2018 and again in March 2019 
to effectively evaluate available evidence. The databases searched were CINAHL, Cochrane 
Database of Systematic Reviews, and PubMed. Keywords and MESH terms included 
mammography, age factors, adverse effects, benefits, risk factors, BRCA1/2 mutations, family 
history, chest radiation outcomes, breast neoplasms, breast cancer, and screening alone and in 
combinations. Gray area literature and search engines utilized were ACOG, ACR, ACS, CDC, 
NCCN, UpToDate, and USPSTF. Reference lists of preliminary research articles were scanned 
for articles that could be considered for further review. Inclusion criteria were: articles published 
between 2008-2019 for the most current data and existing practices recommended to the public 
and health care providers regarding BCS, and articles written only in the English language. A 
total of 136 articles were found, 21 were selected for further consideration based on the inclusion 
criteria, and 8 were included in this review. Articles excluded did not further clarify and answer 
the reviews aim in evaluating best practice management of BCS for women aged 40-49. Multiple 
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studies that were reviewed included meta-analysis’, systematic reviews, 
prospective/retrospective studies, and practice guideline recommendations. The evidence was 
evaluated using the John Hopkins Research and Non-Research Evidence Appraisal Tools (2012a, 
2012b) and rated for quality (Appendix C).  The articles presented in this paper range from Level 
I A to III C. 
Review of Literature 
 After thorough examination of the current evidence, the leading arguments of the 
potential risks and benefits of BCS practices are described to help educate the author and readers 
to make informed, comprehensive decisions about breast health. The themes of possible 
disadvantages towards screening women ages 40-49 are false-positive recalls from 
mammography, false-positive readings leading to biopsy, overdiagnosis of breast cancer leading 
to potential unnecessary treatment, psychological stress, and mammography related radiation 
risk. Beneficial themes of screening women ages 40-49 reviewed are earlier stage of breast 
cancer diagnosis, decreased breast cancer related mortality, increased number of lives saved from 
routine BCS, and the potential of years of life gained from earlier detection (Appendix C).  
Disadvantages to Breast Cancer Screening with Mammography (for women aged 40-49) 
 False-Positives. The potential risk for women receiving a false-positive finding from a 
mammogram that is truly negative for breast cancer has been documented as a considerable 
factor that can influence the individual decisions towards BCS. Pace and Keating (2014), the 
USPSTF, and the ACS systematic reviews demonstrate a 61.3% (95% CI) risk of receiving at 
least one false-positive finding over 10-years for women who started annual screening at age 40, 
and 41.6% (95% CI) respectively for those continuing with biennial screening (Nelson et al., 
2016b; Oeffinger et al., 2015). However, comparable estimates for false positives in women 
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starting mammogram screening in their 50s were discovered at 61.3% (95% CI) annually and 
42% biennially (Nelson et al., 2016b; Oeffinger et al., 2015; Pace & Keating; 2014). This 
evidence shows women in their 40s will experience near identical estimates of false-positive 
recalls compared to those in their 50s regardless of the screening interval. The Van den Ende et 
al. (2017) systematic review examined the effects of BCS for only women aged 40-49 and found 
a 20.5% cumulative risk of experiencing a false-positive finding within the first seven 
mammograms. This finding suggests there is possibly lower rates of false-positives findings 
indicating some variability for women aged 40-49 than reported by the USPSTF, ACS, and Pace 
and Keating (2014) systematic reviews. The decision to choose whether this disadvantage 
outweighs to begin mammogram screening during age 40 or 50 should be the choice of the 
individual undergoing the intervention rather than the standardized guidelines produced by 
governing institutions.   
Myers et al. (2015) found false-positive mammograms leading to biopsy 
recommendations for a first time screen increased with age (OR 1.40 aged 40-44, 1.75 for 50-54 
years, and 1.75 for 55-59 years). Over the course of ten years, cumulative estimates of biopsy 
recommendation from false-positive mammograms exhibit a 7% (95% CI) increased risk during 
annual screening for women in their 40s versus a 9.4% risk for women in their 50’s (Myers et al., 
2015; Nelson et al., 2016b; Oeffinger et al., 2015). During biennial screening, the risk for false 
positives for women in their 40’s was 4.8% versus 6.4% for women in their 50s (Myers et al., 
2015; Nelson et al., 2016b; Oeffinger et al., 2015). These results show that women in their 50’s 
carry a higher risk for false positives than women in their 40’s regardless of annual or biennial 
screening. This suggests the need to avoid the risk for false-positive findings with follow-up 
recommendation for additional imaging or biopsy remains consistent at any age, and should not 
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be a limiting factor with beginning screening at age 40 versus 50. Factors that could contribute 
and affect false positive rates include breast density, type of imaging modality utilized, 
postmenopausal hormone therapy, timing of first mammogram, interval rescreen rate, and lack of 
comparison mammogram images (Nelson et al., 2016b; Oeffinger et al., 2015). Modifiable and 
non-modifiable risk factors are not discussed with this study and could impact these results.  
Overdiagnosis. Overdiagnosis might be considered the greatest harm for a woman 
obtaining mammogram imaging. Overdiagnosis is defined as the diagnosis of “cancer with a 
screening test (such as a mammogram or PSA test) that will never cause any symptoms. These 
cancers may just stop growing or go away on their own” (National Cancer Institute, n.d.). The 
ACS, USPSTF, Myers et al. (2015), Pace and Keating (2014), and van den Ende et al. (2017) 
systematic reviews state overall predication estimates for breast cancer overdiagnosis range 
widely from 0-54% due to varying measures such as the BCS practices utilized, disease 
incidence with or without screening, inclusion or exclusion of ductal carcinoma in situ, and lead 
time adjustments (described as the time gained before cancer incidence from early detection) 
(Nelson et al., 2016b; Oeffinger et al., 2015). Furthermore, no one individual has the same 
underlying predisposing risk factors, behavioral influences, values, socioeconomic status, and 
access to resources. Due to the variability in estimating the impact of breast cancer overdiagnosis 
from mammograms, Myers et al. (2015) and Oeffinger et al. (2015) determined the quality of 
quantifiable data to be low. The ACS, USPSTF, Myers et al. (2015), Pace and Keating (2014), 
and van de Ende et al. (2017) share the understanding that it is difficult to quantify the impact of 
overdiagnosis because there lacks a clear consensus on the best approach of how to measure and 
evaluate this outcome (Nelson et al., 2016b; Oeffinger et al., 2015). Without demonstrating 
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sound quality evidence in the rates of overdiagnosis related to BCS, it is difficult to synthesize 
this factor as an influence toward guideline recommendation and provider-to-patient counseling.  
Psychological Impact. The USPSTF considers and accounts for the potential negative 
psychological impact, that mammography screening may have on women, as a ‘harm’ to BCS 
screening (Nelson et al., 2106b). USPSTF found that women who had negative mammogram 
results experienced less anxiety and distress than those with other outcomes (Nelson et 
al.,2016b). Mixed results were reported and not found significant among for women not 
returning to their next scheduled mammogram after experiencing a previous false-positive result 
(Nelson et al., 2016b). Pace and Keating (2014) suggest that women with false-positive findings 
experienced higher levels of situational distress but did not elicit the diagnosis of major 
depressive or anxiety disorder. Evaluating the extent of individualized concern caused by factors 
from potential negative outcomes of screening is a subjective finding that is balanced differently 
for each patient and difficult to translate across a general population.  
Mammography Radiation Risk. There are currently no studies that directly measure the 
risk of cumulative mammography radiation induced breast cancer (Nelson et al., 2016b; van den 
Ende et al., 2017). Rather, the USPSTF reports modeling studies predicted women aged 40-59 
years experienced 11 per 100,000 radiation induced breast cancer deaths and 2 per 100,000 for 
women aged 50-59 (Nelson et al., 2016b). ACOG (2017) states 125 of 100,000 women receiving 
annual mammography ages 40-74 were diagnosed with radiation induced breast cancer from 
mammograms that resulted in 16 deaths, but 968 breast cancer deaths were averted by screening. 
These estimates elude that the possibility of avoiding multiple breast cancer deaths by decreasing 
radiation exposure, may outweigh the potential risks of mammography to screen for cancer and 
save other lives.  
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Advantages of Screening (for women aged 40-49) 
Surveillance mammograms have been identified as an effective screening tool for 
identifying breast cancer and when done before an individual becomes symptomatic, early stage 
diagnosis and successful treatment with cure is higher. If breast cancer is found to be localized at 
the time of diagnosis, the five-year survival rate is 98.8% (SEER, 2018). Screening findings with 
advanced cancer stages, has a five-year survival rate of 27.4% (SEER, 2018).  
Earlier Diagnosis Stage. Mammograms conducted in women aged 40-49 offer the 
opportunity to begin provider-to-patient education sooner, diagnose breast cancer earlier, treat 
more successfully, and reduce overall mortality (Shen et al., 2011). A 10-year retrospective study 
comparing women aged 40-49 with mammography (145) and non-mammography (166) detected 
breast cancer exhibited smaller average tumor diameter size (20.68 mm versus 30.38 mm; 
p<0.0001), less sentinel lymph node involvement (p<0.0001), increased 5-year disease free rate 
(94% versus 71%) and better overall survival estimates (97% versus 78%) (Shen et al. 2011). 
This statistically significant data demonstrates that females in their 40s who are at average risk 
for developing breast cancer and receive mammograms earlier than the USPSTF’s 
recommendations have better outcomes for earlier diagnosis, less reoccurrence or metastatic 
spread, and less mortality rates (Shen et al., 2011). Women ages 45-49 and 50-54 experience the 
same burden of disease (about 15% of years of life lost per age bracket) (Oeffinger et al., 2015). 
Even with this knowledge, current practice guidelines conflict and differ amongst each other 
prohibiting a cohesive standardized decision making model.  
Decreased Mortality. Reduced breast cancer mortality in women who begin screening 
with mammography in their 40s is evident across the majority of studies (Magnus et al., 2011; 
Myers et al., 2015; Nelson et al., 2016a; Oeffinger et al., 2015; Pace and Keating, 2014). Van 
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den Ende et al. (2017) report in their systematic review of four articles reviewing two 
randomized controlled trials (the Age trial and the Canadian National Breast Screening Study-I 
(CNBSS-1)) that there was no statistically significant difference found in breast cancer mortality 
for women screened ages 40-49 years. However, van den Ende et al. (2017) identifies limitations 
in both studies where the quality of mammogram technology and radiology interpretation in the 
CNBSS-1 trial were possibly sub-standard, and in the Age Trial, after the initial mammogram, 
all subsequent screenings were completed as single view instead of the standard two view 
screening mammogram. Van den Ende et al. (2017) demonstrates the only non-significant 
finding concerning breast cancer mortality reduction with screening women routinely in their 
40s.   
Magnus et al. (2011) meta-analysis found a 17% mortality reduction for women who had 
screening mammograms between ages 39-49. Myers et al. (2015) and Pace and Keating (2014) 
systematic reviews found a 15% mortality reduction for women beginning screening less than 50 
years. The ACS graded the outcome of reduced breast cancer mortality evidence in women 
younger than 50 as high (Oeffinger et al., 2015). The 5-year absolute risk of women developing 
breast cancer at 5-year intervals is: 0.6% during ages 40-44, 0.9% during ages 45-49, and 1.1% 
during ages 50-54 (Oeffinger et al., 2015). Mortality reduction is clearly evident in women 
receiving mammograms earlier than 50.  
Lives Saved/Potential Years of Life Gained. It is undeniable that mammography is the 
best available diagnostic imaging modality and gold standard for detecting breast cancer (World 
Health Organization, 2018). Pace and Keating (2014) found in their systematic review that 5 out 
of every 10,000 women aged 40-49 years, 10 out of every 10,000 women aged 50-59 years, 42 
out of every 10,000 women aged 60-69 years will be saved from mammograms. The USPSTF 
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found biennial mammography for women aged 40-74 gained 152 lifetime years and avoided 
eight breast cancer deaths per 1,000 versus women aged 50-74 gained 122 total years of life and 
avoided seven breast cancer deaths (Sui, 2016). The ACR estimates based on their recommended 
screening strategy, women receiving annual screening ages 40-84 per 1,000, experienced 11.9 
BC deaths prevented, and 189 years of life gained (Monticciolo et al., 2017). ACR estimates 
using the USPSTF’s recommendation for biennial mammography from ages 50-74 that 6.95 BC 
deaths are prevented, and 110 years of life are gained (Monticciolo et al., 2017). Evidence 
suggests those screened earlier and more frequently have the potential to experience lengthier 
lives and fewer deaths. 
Rationale 
Theoretical/Conceptual Frameworks. The theoretical framework that will guide this 
project is Jean Watson’s Philosophy and Science of Caring that encompasses the concepts of 
human being, health, environment, and nursing (Petiprin, 2016). Watson identifies the human 
being as a unique individual that requires the time, patience, and respect to be understood and 
valued. She defines health as the physical and mental levels of well-being with efforts towards 
the absence of disease. The environment focuses on health care professionals and their exposure 
to socio-cultural experiences that provides opportunity to interact, reflect, and grow. Cultivating 
personal and professional self-awareness allows for the provider to be present, non-judgmental, 
and engaging in a caring manner with the patient. Watson’s model is parallel to the nursing 
process in creating and establishing a comprehensive care plan that is holistic in nature.  
Watson’s framework is grounded in approaching all human interactions in a caring 
inquiry to promote health while valuing patient autonomy (Petiprin, 2016). These fundamental 
concepts are what will structure the approach towards communicating and understanding 
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perceived patient perceptions and values. BCS addresses health as a collaborative process 
between provider and patient, encouraging establishment of a comprehensive care plan, and 
ultimately optimizing breast health outcomes for each individual patient, instead of categorizing 
patients into groups, costing lives. 
The Tannahill Model of Health Promotion is the formative theory that will represent this 
project’s approach towards identifying and addressing breast health among women. This model 
aims at health promotion by incorporating community-based education through dissemination of 
best available evidence, protection through policy implementation, and prevention or early 
detection of disease through modern medicine (Tannahfill, 2009). This model will demonstrate 
health promotion of female breast health through analyzation of current literature, sharing this 
information to the health care team at FQHC, and implementing an easy-to-use standard of 
practice toolkit to open a pathway for discussing and offering secondary screening measures for 
breast cancer.  
The “appropriateness in patient care” is the conceptual framework that will be the 
foundation in creating an algorithm for the Screening Mammogram Initiation Protocol (SMIP) at 
FQHC. This will also help formulate the approach and process of how providers are to lead 
consultation with their patients regarding breast health.  Sharpe & Faden (1996) proposes 
“appropriateness” is characterized by valuing three point of views of the clinician, the patient, 
and the society. This framework emphasizes clinical recommendation by the health care provider 
are to be based on counseling best available literature. Discussion of all the available options and 
their potential outcomes with consideration of the patients’ values and preferences are integral 
components of valuing “appropriateness” (Sharpe & Faden, 1996). This concept in patient care 
highlights the significance of informed consent that is based on evidence, is non-biased, and a 
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process of shared decision making between the patient and the provider. As critical as it is for a 
clinician to disseminate information on recommended medical interventions while weighing the 
health benefits versus risk for each patient, if the proposed intervention does not align with the 
patient’s principles, then it is considered inappropriate to implement at that visit.  
While treating the whole person in a holistic manner, it is essential to integrate scientific 
knowledge to ensure optimal patient outcomes. Evidenced based practice theory is the 
fundamental guide for the purpose of this Doctorate of Nursing Practice (DNP) project and 
efforts toward a practice change at FQHC. This theory promotes the dissemination of high-level 
research based on a hierarchal ladder into clinical practice. Translating evidence into the health 
care delivery system improves medical care and is vital towards meeting public health needs 
(Institute of Medicine, 2001). However, while evidence can be generalized in the efforts of a 
high-level study, sometimes evidence based practice theory can be contradictory in practice as 
the population is not generalized and may require more individualized approaches. Each patient 
is an individual with different values that are uniquely influenced by their social, environmental, 
spiritual, cultural beliefs, and experiences. This is a reminder that a harmonious balance between 
medicinal science and patient intervention is a collaborative process which urges an informed 
decision, requiring clinician dissemination of information and patient-centered decision making.  
Specific Aims  
By February 2019, primary care providers at the FQHC will receive an educational 
module on BCS guidelines, understand the importance of the evidence behind the current 
guidelines, and apprehend techniques for individualized approaches to screening mammograms 
using the Screening Mammogram Initiation Protocol (SMIP), developed by the author as a tool 
for aiding decision making for best screening initiation timeframe and cancer risk assessments 
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(Appendix K). The providers will be able to participate in shared decision making, using an 
evidence based standardized approach. Screening may start early for some women, compared to 
the current approach of starting all women at age 50. Appropriate recommendation of care will 
be coordinated by achieving each of these objectives with the SMIP:  
● Evaluate current best evidence and create an algorithm for breast cancer mammogram 
screening appropriate to risk and age for each female 
● Assess and evaluate best approaches for successful implementation of algorithm   
● Present educational session and implement SMIP into practice  
● Improve provider knowledge and counseling/recommendation for mammogram with 
female members  
Section III: Methods 
Context 
 The SMIP protocol will be implemented using an educational and integrative approach. 
Education regarding BCS, discussion about guidelines, a review of current practice and risks, 
along with implementation of this algorithm in the clinic work flow to achieve full 
implementation of this protocol will be applied.   
Stakeholders 
 Key stakeholders that will be directly involved with this project proposal include the 
DNP student, DNP chair, site leader, general practitioners, clinic management, and clinic staff. 
Recipients that will be affected by this intervention include female patients and their families of 
FQHC, their insurances/government, diagnostic testing centers, and specialty oncology clinics.  
Interventions 
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After reviewing the current BCS guidelines and risk factors, the SMIP will be created by 
the DNP student. The SMIP is an evidence-based strategy designed as an algorithm for 
healthcare providers to educate and navigate women about their breast health throughout their 
life trajectory. This screening provision is an opportunity for professional development among 
healthcare professionals, a public outreach initiative to promote screening on disparate 
populations, and improvement on quality and assurance of reproductive services provided 
(National Breast and Cervical Cancer Early Detection Program [NBCCEDP], 2013). After 
collaborating with the DNP chair and site leader for the SMIP approval, the DNP student will 
meet with the FQHC director for project proposal and approval to implement the project. 
Education of providers will occur during one of their monthly, morning provider training 
meetings. A 10-minute PowerPoint presentation will be provided as an in-service to FQHC staff 
with handouts of the SMIP. Pre-surveys from the providers will also be collected.  
The SMIP will be initiated the following week for 9-weeks for data collection. Currently, 
identified from I2I Tracking the medical assistants highlight female patients age 50-74 that are 
due for their biennial mammogram and are listed for clinical visits the following day. During 
their visit, either the medical assistant will ask if the patient needs a mammogram referral request 
and if they have further questions a discussion with the provider can occur. With the SMIP, 
identifying patients the day before will be eliminated. Instead, during the rooming process the 
medical assistants will review with female members ages 40 and 45, their risk factors for breast 
cancer (that can include the Gail Model assessment), then record and report findings to the 
treating provider. From those responses, the provider will be able to guide the discussion about 
the patient’s individualized breast cancer risks and help the patient make an informed decision 
about mammography screening. From the providers documentation, the patient’s preference on 
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the interval for mammograms will be viewable for future management in secondary screening 
care. Post surveys will be collected by the DNP student completed by the providers at the end of 
the project implementation. Analyzation of all data collected from pre/post surveys and I2I 
Tracking will be completed by the DNP student with assistance from Dr. Sandhu.  
By integrating the SMIP into FQHC’s practice, the project will offer overall greater 
awareness towards screening services for all female members, an EHR system with I2I Tracking 
that aligns and supports provider practice changes, a reduction in barriers and increased access to 
BCS (NBCCEDP, 2013). Increased and appropriate BCS, re-screening, and surveillance will 
impact health outcomes by reducing breast cancer morbidity and mortality, and reduce health 
disparities.  
Gap analysis  
 The current standards of practice for mammogram screening at the FQHC follow the 
USPSTF guidelines. The USPSTF recommends biennial mammograms for women 50 and over 
who are at average risk until age 74 (Siu, 2016). A Family Nurse Practitioner at the FQHC 
initially shared concern over when to start the conversation with patient’s about BCS, when to 
order mammography, and when to schedule follow-up imaging. He and other providers at the 
FQHC shared despite the governing USPSTF guidelines that initiate mammogram screening at 
age 50, there is no screening for any additional risks, or educating women about the possibility of 
starting earlier or at more frequent intervals. Mammograms are then continued biennially as per 
the recommendations of the USPSTF. Furthermore, considering females with breast cancer risk 
factors, there is no standard at FQHC guiding provider practices among earlier initial screening 
age, frequency, discontinuation, as well as mammogram test result recommendations for next 
routine follow-up. 
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The lead Nurse Practitioner for this project was interviewed for a detailed gap analysis 
(Appendix D and E). The NP site leader expressed BCS and follow-up varies not only among 
providers, but also among different organizations, citing that every unremarkable radiology 
imaging report recommends to schedule the next mammogram in one year. This 
recommendation directly conflicts with the USPSTF’s guidelines to image every 2-years for an 
average risk patient. From his interactions, other providers have expressed similar opinions and a 
general consensus of confusion with when to start, rescreen, and discontinue mammogram 
practices with their female population.  
 At the FQHC, I2I Tracking is a repository system that extracts electronic health record 
data from NextGen for the institution to understand areas of high performance and needs for 
improvement to support quality health outcomes, efficiency, and financial responsibility. 
Utilization of I2I Tracking found between the 12 months of September 2017-2018, 838 females 
ages 50-74 (parameters determined based on the FQHC’s current standards of care adopted by 
the USPSTF guidelines) were eligible for breast cancer mammograms. Out of those 838 females, 
599 were referred by clinicians and received mammograms showing a near 72% compliance. 
When age parameters were expanded from ages 40-74 (based on the ACOG, NCCN, and ACR’s 
initial start age), 1322 females at the FQHC were eligible and 837 females were referred and 
received mammograms reflecting a 63.7% rate of mammography screening. This data suggests 
that provider practices are inconsistent with current FQHC standards for BCS mammography, 
and/or risk factors are not cohesively identified to implicate initiating earlier mammogram 
referral.  
GANTT 
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 This DNP project will take place from October 2018-April 2019. A GANTT chart 
illustrates the proposed project’s timeline (Appendix F). Each task is reflected with which month 
each of these milestones are planned to be completed. These tasks follow the nursing process by 
first identifying the needs of FQHC’s clinic through assessing the work environment and then 
determining a project idea. Planning will occur through a literature review and creating a practice 
based screening tool (SMIP). Implementation is conducted with an educational presentation with 
subsequent utilization in clinical practice for nine-weeks. This will simultaneously follow an 
evaluation with data collection and analysis. Lastly, the DNP student will complete the project 
summary and write-up to further disseminate the overall findings.  
Work Breakdown Structure 
The primary responsibility of the development, planning, implementation, and evaluation 
of this project is the DNP student (Appendix G). The DNP student will facilitate, coordinate, and 
lead this project with the support of the DNP chair, Dr. Sandhu and the clinical site mentor. The 
DNP student will work with Dr. Sandhu to develop the Screening Mammogram Initiation 
Protocol (SMIP). The DNP student will provide an educational PowerPoint in-service, and help 
implement the SMIP. The Site Leader will extract the data collected on I2I Tracking for analysis. 
Health Care Providers and Medical Assistants will utilize the SMIP into clinical practice over a 
nine-week period. The DNP student will be able to utilize information collected from I2I 
Tracking and surveys to evaluate the projects efficacy and success.   
SWOT Analysis 
An analysis of the strengths, weaknesses, threats, and opportunities to the project have 
been performed to identify foreseeable issues with proposed solutions to support the success of 
this project (Appendix H).  
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Strengths. The FQHC’s health care providers have expressed a need to better address 
and counsel patients on BCS and referral for mammograms. Integrating a standardized process 
will help maintain accountability to aid in prompting providers when their patients are due for 
mammogram screening discussion. Easy access of the algorithm with printed laminated handouts 
will help appropriately guide the screening process to improve identification of women eligible 
for mammography and are to receive counseling. This project has the opportunity to increase 
provider knowledge, enhance patient involvement, and provide both patient and provider 
empowerment in making decisions. Subsequently, this will foster collaborative discussions with 
members to promote patient centered care. Ultimately this can increase patient satisfaction scores 
and improve continuity of screening services, early detection, and referral for treatment in 
primary care.  
Weaknesses. Potential issues that exist and challenge this project’s success include a lack 
of a currently existing algorithm, differing views and/or limited time from providers, a lack of 
opportunity within the timeframe of the intervention, and possible lack of participation from the 
patients, given the time constraints and needs for enhanced education. A change in any protocol 
can be confusing for patients and take time to adopt. Development of an algorithm that has never 
been tested requires dedication and time to research and formulate. Utilization in a confined 
period can hinder the potential of a larger sample size for analysis. Health care providers may not 
prioritize BCS discussion in comparison to other acute health issues. Providers may also not 
have sufficient time between visits to optimally discuss breast health due to the lack of resources. 
Beliefs and values of the patient based on culture and/or religion can affect patient opinions of 
obtaining mammograms. Modern medicinal practices can be considered an invasive intervention 
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in comparison to complementary alternatives such as the connectedness of spiritual healing and 
consciousness of balance between all elements that is practiced in Native American culture.  
 Opportunities. A culture shift is occurring towards emphasis on preventative health and 
screening in primary care. Many opportunities exist to improve the quality of care at FQHC. 
Including BCS discussions as part of the routine well women annual exam will raise awareness 
and promote holistic care. The Centers for Medicare and Medicaid created an electronic clinical 
quality measure, CMS125v6 to monitor the 2018 performance of women ages 50-74 obtaining 
mammograms to screen for breast cancer (Electronic Clinical Quality Improvement Resource 
Center, 2018). Starting screening early in some females and ensuring that screening will happen 
by age 50 for all females, will help the FQHC meet the goals of quality healthcare. The use of a 
standardized protocol will create a flow for early conversation and hopefully mitigate further 
delays in achieve successful screening mammogram rates. Production of this measure highlights 
the importance of monitoring screening rates in primary clinical care. The United States 
Department of Health and Human Services Health Resources and Services Administration (n.d.) 
further developed a detailed overview of the BCS quality measure to emphasize the importance 
of addressing high quality assurance in healthcare to improve outcomes.  
Effective screening will improve Healthy People’s 2020 target goals towards reducing 
health disparity rates of cancer related “illness, disability, and death” (Office of Disease 
Prevention and Health Promotion, 2018a). The National Committee for Quality Assurance 
(2018) Healthcare Effectiveness Data and Information Set shows the 2017 BCS rates based off 
of insurance coverage within the last two years among women ages 50-74 were 72.7% for 
commercial Health Maintenance Organization (HMO) insurance, 70.2% commercial Preferred 
Provider Organization (PPO) coverage, 58.3% HMO Medicaid, 72.5% HMO Medicare, and 
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72.2% PPO Medicare. This clinical performance shows up to a 13.9% range in variability of 
screening rates, suggesting the type of care coverage an individual has contributes towards the 
quality of comprehensive health sought and delivered. In 2016, “only 22% of uninsured women 
aged 40-64 received a mammogram in the past year, compared to 54% of insured women” 
(American Cancer Society Cancer Action Network, 2016, para. 2). Furthermore, females not 
getting screening included 30% not insured, 62% uninsured, 25% college graduates, and 47% 
with less than 12 years of education further potentiating socioeconomic disparities (American 
Cancer Society Cancer Action Network, 2016).  
 Threats. Foreseeable threats that challenge the success of this project are the varying 
institutional and government agency guidelines on BCS, cultural/language barriers, and 
misinterpretations or errors of the algorithm. Adapting reputable guidelines onto one document 
will reflect the best attempt at integrating, while respecting all current screening 
recommendations but will not have proven generalizability. However, this will promote patient-
centered care and decision making that will be established with the provider.  
Budget 
This project will not require significant financial cost, rather a commitment of time from 
the stakeholders and those directly affected by the intervention (Appendix I). Cost of supplies for 
the educational presentation is projected to be about $110 and the student developing, 
implementing, and evaluating this project will not be financially compensated. The presentation 
will be conducted during the FQHC’s monthly required provider in-service training meetings. 
Implementation of the SMIP will occur during a patient’s well-women annual visit and will be of 
no extra cost. Due to the Affordable Care Act, women are no longer discriminated by health 
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insurance coverage and have access to preventative care without cost-sharing (National 
Women’s Law Center, 2013).  
The economic burden of cancer in the United States in 2010 were estimated to be $124.5 
billion, $16.5 billion towards female breast cancer as the highest cancer cost (Yabroff et al., 
2011). In the United States an average cost of a mammogram for an uninsured individual is 
$102, with Oakland, CA $130 respectively (Cost Helper, 2018b and New Choice Health, 2019). 
However, all new health insurance companies after the Affordable Care Act was initiated in 
2012 are required to cover mammograms every one to two years for women over 40 years 
without cost-sharing or co-payments (National Women’s Law Center, 2013). Breast cancer 
treatment varies by stage and can involve surgery (i.e. lumpectomy or mastectomy), 
chemotherapy and/or biotherapy, radiation, and other ancillary treatments for symptom 
management, adverse or side effects, and unanticipated hospitalizations.  
Insured patients receiving breast cancer treatment can easily reach their yearly out-of-
pocket maximum from labs, copays for prescription drugs, physician visits, and individual drugs 
or treatments not covered by their insurance plan (Cost Helper, 2018a). For patients without 
insurance, surgery costs range from $15,000-$50,000, chemotherapy $10,000-$100,000 (or 
$7,000-$40,000 per treatment), with a total costs of treatment averaging $100,000 to $300,000 
for advanced cases (Cost Helper, 2018a). For an average risk women ages 45-65, there is a 1:21 
chance for developing breast cancer (ACS, 2013). For every 21 mammograms for uninsured 
females it will cost $2142, less than any single treatment modality for diagnosed breast cancer 
that typically is comprised as multi-regimen.   
Communication Matrix 
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Integrating each organization’s recommendation into an easily comprehensible and 
usable toolkit will require current evidence-based research and planning (Appendix J). Project 
research, development, coordinating, and facilitation of this project will be the primary 
responsibility of the DNP student. Continual communication with the DNP chair and site leader 
will be conducted as appropriate to the project needs via in-person, email, and phone.   
Outcome Measures 
 Based on current best evidence, the DNP student with guidance from the DNP chair, will 
create the SMIP intervention to standardize mammogram screening and referral in primary care. 
This intervention will help reduce missed screening opportunities due to a standardized protocol 
that integrates current evidence with EHR prompt reminders. This proposed intervention will 
improve health care provider knowledge and confidence to educate and offer appropriate 
referral. Outcome measures for this project’s intervention will reflect the following:  
● At least 80% of providers will increase their knowledge of when and how to counsel 
female members about breast health. 
● At least 25 patients will receive counseling/recommendation for mammogram using the 
SMIP starting at age 40. 
● At least 50% of the providers will acknowledge satisfaction with utilizing the SMIP 
algorithm for BCS. 
Analysis  
 Qualitative data will be collected through pre and post educational and implementation 
surveys completed by health care providers at the FQHC. This data will reflect on the quality of 
the education provided, the feasibility using the SMIP algorithm, and open feedback from 
providers implementing the intervention. Quantitative data will be comprised of general and 
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anonymous information collected from the electronic I2I Tracking. Data for analysis will include 
the number of females starting BCS at age 40 and 50, and the number of females eligible and 
referred for a mammogram. Quantitative information from the electronic I2I Tracking will be 
extracted into Excel spreadsheet software for analysis and evaluation. Planned data analysis will 
include the change in percent of knowledge, the change in percent of patients referred for 
mammogram, and the percentage rates of satisfaction using the Likert scale.  
Ethical Considerations  
 This project focuses on quality improvement using evidence-based change in clinical 
practice (Appendix A). This project examines BCS practices before and after the project’s 
intervention to female members at the FQHC that are primarily high-risk and have less access to 
resources. Competing reputable organizations recommend differing BCS practices that are 
notably earlier than the FQHC’s current standards of practice that follow the USPSTF 
Guidelines. Health promotion is an on-going and applicable beneficent goal for every patient. 
Health care providers are responsible for educating patients and caregivers by providing 
comprehensive information to facilitate their right to make decisions (American Nurses 
Association, 2015). Health care providers are also responsible for utilizing evidence-based 
medicine in practice where appropriate. Determining appropriateness of screening should not be 
the sole responsibility of the provider, when guidelines that vary exist. Despite cultural/religious 
preferences, language barriers, or personal biases, it is a provider’s “authority, accountability, 
and responsibility [to] take action consistent with the obligation to promote health and provide 
optimal care” (American Nurses Association, p. 7, 2015). Counseling on all opportunities to 
screen should be based on the values of patient benefits versus harm and is a collaborate and 
autonomous discussion between patient and provider. This project is a non-research project 
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which will evaluate a quality improvement method, and does not require IRB approval 
(Appendix A). 
Section IV: Results  
Results 
 A total of 25 staff members (nurses, behavioral health, social work, advanced practice 
providers, physicians, and CEO) participated in the BCS educational presentation. Eleven 
providers participated in the pre/post knowledge surveys and nine completed the nine-week post-
implementation evaluation (Appendix N). I2I Tracking recorded the number of eligible female 
participants for BCS and the number referred by providers based on the age ranges of 40-49 and 
50-59 between February 6th- April 10th, 2019 (Appendix O).  
Pre/Post Knowledge Surveys. The pre knowledge survey was administered prior to the 
start of the educational, in-person presentation with the post knowledge survey provided after 
presentation completion (Appendix L). Questions one and two asked providers how well they 
understood the current BCS protocol at the FQHC of average and high-risk female patients with 
available options as ‘less than I would like’, ‘about right’, and ‘more than I would like’ 
(Appendix N). Results reflected a 19% and 36.5% improvement after the post-educational 
session. Question three evaluated how versed providers felt in regard to other various screening 
guidelines (ACOG, ACR, ACS, NCCN, USTPSTF) with selections to answer from ‘not at all 
well informed,’ ‘somewhat well informed,’ and ‘very well informed.’ The post knowledge 
survey showed a 26.5% increase where providers felt they were ‘very well informed.’ Question 
four supported a near unanimous response that providers felt it was ‘very important’ that patients 
receive counsel about mammogram screening guidelines to make individualized screening goals 
based on risk assessment. Only one response in the post knowledge survey chose it was 
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‘somewhat’ important to provide shared-decision making BCS. Ninety percent answered 
(previously 82%) that at this time they were ‘very likely’ to implement an individualized 
screening protocol based on risk factors. One answered in the post knowledge survey they would 
‘somewhat likely’ utilize the SMIP. Free response feedback of “great work, I feel well informed 
after your lecture” and “thanks ☺” were written in the post-education.  
Post Implementation Survey. The post implementation survey was provided by the 
clinical site mentor at the subsequent FQHC staff meeting on April 10th, 2019 (Appendix L). 
Eighty-nine percent felt ‘very comfortable’ using the SMIP after nine-weeks and 11% felt 
‘somewhat comfortable’ (Appendix N). In question two, 89% answered that it was ‘very 
feasible’ to incorporate the project into a women’s annual exam and 11% ‘somewhat feasible.’ 
Fifty-five percent of providers responded ‘yes,’ that they were more engaged in making BCS 
decisions with their patients using the SMIP, 33% ‘somewhat,’ and 11% ‘not at all.’ As a 
provider, 89% replied ‘yes’ that they saw value in initiating the SMIP protocol, 11% 
‘somewhat,’ and 0% ‘not at all.’ Open feedback responses were “Not sure if I’m really using this 
protocol, I use the USPSTF recommendations,” “I love laminated patient education tools!,” 
“great job! Go dons!,” and “great work! Great protocol.”   
I2I Tracking Results. The electronic I2I Tracking system found after nine-weeks from 
the start of implementation that out of 842 women aged 40-49 that were eligible for BCS, 609 
received referrals from their providers (Table 5 & Appendix O). Seventy two percent were 
screened during the implementation phase in comparison to 64% pre-project. For women aged 
50-59, 555 were eligible for BCS, 445 were referred from their providers, and 80% were 
screened (previously 73%). 
Table 5: 
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Age  Percent Screened Pre Project  
9/10/17-9/10/18 
Percent Screened Post Project Implementation  
2/6/19-4/10/19 
40-49 64% 72% 
50-59 73% 80% 
(I2I Tracking search)  
Section V: Discussion 
Summary  
 Although there were minimal unfavorable responses in the pre/post knowledge and post-
implementation surveys, overall feedback was positive and exceeded all desired project 
outcomes. Providers responded that they better understood the various BCS guidelines and the 
FQHC’s BCS protocol for not only average risk, but also high-risk female patients. Providers 
weighed near unanimous importance in counseling women about their breast health and choosing 
when to start mammography based on individual risk factors. Nearly 90% of providers 
acknowledged satisfaction using the SMIP and during the nine-week implementation, 609 female 
patients ages 40-49 received provider referral for mammography.  
Interpretation  
 For women under age 50, an 8% increase in the number of women who were referred for 
mammograms was observed. Based on these I2I Tracking results, however only an assumption 
can be made that the SMIP protocol was followed, since no direct patient or provider data was 
analyzed. For women aged 50-59, a 7% increase in mammogram recommendation referrals were 
completed by providers, improving FQHC’s BCS practice protocol, Health People 2020’s 
initiatives C17 and 18.1, and meeting all various screening recommendations (regardless if it is 
the latest start age for their respective guidelines). It can be inferred that this project’s 
educational session and non-validated SMIP tool improved provider knowledge and 
understanding of BCS and supported comprehensive counseling for women to make informed 
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decisions about their breast health. It can be inferred that toolkits identifying women at risk for 
breast cancer or place higher value in the benefits of mammography over the ‘harms,’ are 
necessary in primary care to support the opportunity for earlier screening and potential diagnosis. 
It can be concluded that at this time there is no clear consensus on BCS recommendations, but 
rather it should be the choice of the patient after non-biased counsel by their respective provider. 
Instead of examining the number of completed mammograms, reimbursement measures should 
rather measure the number of women who received counseling on BCS.  
Limitations 
 Unavoidable limitations without breaking HIPAA and requiring the assistance from the 
informational technologist to build tracking features in the EHR were if patients completed their 
mammogram after a referral was made, and if patients who received comprehensive BCS 
counsel by their respective provider chose not to have a mammogram at that time. Future studies 
examining the barriers for women to complete their screening mammogram and factors weighing 
the decision for or declining to start mammography are suggested to better improve the SMIP 
and overall BCS. A confounding variable that could have influenced the outcomes of this project 
was the need for the clinic to meet the 2018 Healthcare Effectiveness Data and Information Set 
(HEDIS) measures. HEDIS tracks and supports funding for FQHC with one measure directly 
examining BCS rates for women aged 50-74 years. The drive for the clinic to meet these 
requirements could have indirectly contributed to the increased rates of referral for women ages 
50-59, but overall is supportive of improved breast health outcomes.  
Conclusions  
In light of advancing technology and the shift towards precision health, primary 
healthcare providers have the opportunity to initiate the discussion and counsel women on the 
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risks, benefits, and limitations of BCS while incorporating patient values and preferences. There 
is an opportunity to promote BCS in various populations and decrease health disparities using 
primary care practice tools such as the SMIP. National goals to increase BCS interventions can 
be met and positively influence quality health care outcomes, screening efficiency, delivery of 
care, financial performance, and patient-provider satisfaction. Shared-decision making between 
provider and patient coupled with standard breast screening guidelines can ultimately empower 
women about breast health and improve patient outcomes. 
Section VI: Other Information 
Funding 
 This doctoral project received no sources of funding from any organization in the design, 
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Section VIII. Appendices 
Appendix A: DNP Statement of Non-Research Determination 
DNP Statement of Non-Research Determination Form 
Student Name:___Lacrisha Go_______________________                                                                                                                
Title of Project: Standardizing Mammogram Screening in Primary Care: Integrating an 
Evidence Based Approach 
 
Brief Description of Project: Mammogram screening practices for breast cancer vary 
between initial start age, frequency, and discontinuation among reputable organizations. 
Both modifiable and non-modifiable risk factors has caused even further confusion in the 
screening process. This has consequently resulted in inconsistent provider practices 
within primary care and ultimately impacted early identification of breast cancer and its 
mortality. The purpose of this project is to create and implement a breast cancer 
screening algorithm for providers in primary care to identify, assess, collaborate, and 
refer women for mammogram testing using the appropriate guidelines and risk factor 
assessments based on age.  
 
A) Aim Statement: By March 2018, primary care providers at the Federally Qualified 
Health Center (FQHC) will utilize a standardized approach for routine screening 
mammograms using the Screening Mammogram Initiation Protocol (SMIP). 
B) Description of Intervention: The DNP student will create the SMIP and lead an 
educational training session to FQHC health care providers and medical assistants 
about the breast cancer mammogram screening algorithm. Participants will utilize the 
information taught in the presentation to effectively implement and utilize the toolkit 
into practice. Six weeks after initial project implementation, the DNP student will 
connect with project manager to collect statistical information from I2I tracking and 
evaluate intervention’s effectiveness from completed staff surveys.  
C) How will this intervention change practice? This intervention will reduce missed 
opportunities of initial screening by standardizing the breast cancer screening process 
for all female patients at FQHC. It will help increase health care provider knowledge 
and empowerment to counsel and encourage collaboration of comprehensive plans 
with their patient.  
D) Outcome measurements: 1) At least 80% of providers will increase their 
knowledge of when and how to counsel female members about breast health. 2) At 
least 25 patients will receive counseling/recommendation for mammogram using the 
SMIP starting at age 40. 3) At least 50% of the providers will acknowledge satisfaction 
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with utilizing the SMIP algorithm for breast cancer screening. 
 
To qualify as an Evidence-based Change in Practice Project, rather than a Research Project, the 
criteria outlined in federal guidelines will be used:  
(http://answers.hhs.gov/ohrp/categories/1569)  
X   This project meets the guidelines for an Evidence-based Change in Practice Project as 
outlined in the Project Checklist (attached). Student may proceed with implementation. 
☐This project involves research with human subjects and must be submitted for IRB approval 
before project activity can commence. 
Comments:   
EVIDENCE-BASED CHANGE OF PRACTICE PROJECT CHECKLIST * 
 
Instructions: Answer YES or NO to each of the following statements: 
Project Title:  
 
YES NO 
The aim of the project is to improve the process or delivery of care with 
established/ accepted standards, or to implement evidence-based change. There is 
no intention of using the data for research purposes. 
X  
The specific aim is to improve performance on a specific service or program and is 
a part of usual care.  ALL participants will receive standard of care. 
X  
The project is NOT designed to follow a research design, e.g., hypothesis testing 
or group comparison, randomization, control groups, prospective comparison 
groups, cross-sectional, case control). The project does NOT follow a protocol that 
overrides clinical decision-making. 
X  
The project involves implementation of established and tested quality standards 
and/or systematic monitoring, assessment or evaluation of the organization to 
ensure that existing quality standards are being met. The project does NOT 
develop paradigms or untested methods or new untested standards. 
X  
The project involves implementation of care practices and interventions that are 
consensus-based or evidence-based. The project does NOT seek to test an 
intervention that is beyond current science and experience. 
X  
The project is conducted by staff where the project will take place and involves 
staff who are working at an agency that has an agreement with USF SONHP. 
X  
The project has NO funding from federal agencies or research-focused 
organizations and is not receiving funding for implementation research. 
X  
The agency or clinical practice unit agrees that this is a project that will be 
implemented to improve the process or delivery of care, i.e., not a personal 
research project that is dependent upon the voluntary participation of colleagues, 
students and/ or patients. 
X  
If there is an intent to, or possibility of publishing your work, you and supervising 
faculty and the agency oversight committee are comfortable with the following 
X  
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statement in your methods section:  “This project was undertaken as an Evidence-
based change of practice project at X hospital or agency and as such was not 
formally supervised by the Institutional Review Board.”  
 
ANSWER KEY: If the answer to ALL of these items is yes, the project can be considered an 
Evidence-based activity that does NOT meet the definition of research.  IRB review is not 
required.  Keep a copy of this checklist in your files.  If the answer to ANY of these questions 
is NO, you must submit for IRB approval. 
 
*Adapted with permission of Elizabeth L. Hohmann, MD, Director and Chair, Partners Human 




STUDENT NAME (Please print):  
________Lacrisha J. Go___________           __________________________________ 
Signature of Student: 
______________________________________________________DATE____________         
 
SUPERVISING FACULTY MEMBER (CHAIR) NAME (Please print):  
________________________________________________________________________ 
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ACS are a guidance, 
but shared-decision 
making is vital 
between the provider 
and the patient.  
 
Limitations: Many 
factors of each 
individual study 
affecting outcomes 
(i.e. comparison of 
age-groups, imaging 
modality utilized, type 
of screening, patient 
population risk 
factors), and outcomes 













Systematic review of 
harms and benefits of 
BCS. Sources 
analyzed using 
Medline database and 
manual search of 
reference lists and 
current practice 
recommendations. 
Quality of evidence 






































to decrease BC 
mortality and found 
significant for women 
in their 40 through 60 
year ages. Evidence 
shows there is a risk of 
false-positives that is 
higher the younger the 
age. Overdiagnosis 
estimates vary 
between studies and 
reports may be over or 
underestimated. 
Clinical decision 
models can be used to 
help best navigate best 




high, rigorous studies 
needed to understand 
true benefit/harm of 
mammography. BCS 
ought to be 
individualized based 
on risk factors and 
patient priorities.  
 
Limitations: 
Publication date of 
sources vary up to >10 
years ago,  
advancements in 
treatment and imaging 
technology since 






review through the 
Cancer Registry 
Database at an 
unidentified institution 
for women ages 40-49 





























detected cancer were 
found to have at 
diagnosis smaller 
tumor size, less 
sentinel lymph node 
involvement, higher 
disease-free and better 
overall survival rates 
compared with women 
with non-
Implications: Multiple 
benefits of annual 
mammography for 
women starting at age 
40 exhibited.  
 
Limitations: Study 













Systematic review of 
the harms and benefits 
of BCS for women 
ages 40-49. Sources 
analyzed (February 
2017) using Embase, 
Medline, PubMed, and 
Cochrane databases. 
Quality of evidence 


























cause mortality not 
found generalizable 
and graded as 





quality of evidence for 
women ages 40-49. 
Overdiagnosis based 











all studies conducted 
outside the United 
States (differing 
screening practices of 
invitation to screen 




Key: LOE: level of evidence (Johns Hopkins Hospital/The Johns Hopkins University, 2012a, 2012b), IV: Independent variable, DV: 
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Appendix D: Gap Analysis Interview with lead Nurse Practitioner 
1. What are some existing standards of practice policies that you believe can be improved at 
FQHC? 
 
There is a lot of current evidence-based literature that can update and improve our health 
care outcomes of our patients at the FQHC. The name of this clinic indicates a huge 
opportunity to work with vulnerable populations where we can provide comprehensive, 
thorough care to those with many health care needs. Improvements especially for funding of 
our clinic include preventative health and secondary services such as screening for hepatitis, 
HIV, TB, breast/cervical/colon cancer. Especially as DNP students, we have the access and 
tools to make really positive change at a clinic like this.  
2. What is the current process of identifying, managing, and follow-up for this practice and 
existing health outcomes? 
The current process of breast cancer screening is our Medical Assistants print out a sheet 
of all our patients scheduled for the next clinic day. On this list, our I2I Tracking system 
alerts which patient are in need of a preventative health or screening service. From this, 
patients are notified by our panel manager that they are being referred for a mammogram. 
Patients call the number on the referral and then obtain their mammogram at local outside 
facilities. Reports are sent to their primary provider who then follow-up with the patient of 
the results. Our standard of practice policy follows the USPSTF guidelines, but unremarkable 
radiology imaging reports recommend to rescreen yearly. Our policy that is adopted from the 
USPSTF recommends to screen every two years. It is also confusing when we should start 
screening for patients with risk factors and why some women with no significant risk factors 
are receiving mammograms younger than age 50.  
3. Is there available data that can support for the opportunity in change in practice? 
I2I Tracks is a great system used to extract our data from NextGen to help track and 
indicate what preventative health measures are needed for each patient and reflects our 
compliance rates at the clinic. Using I2I Tracks we are able to measure baseline data, 
interventions that have been implemented at the clinic, and evaluate their effectiveness.  
4. What are the desired outcomes for this practice change?  
Outcomes of improving screening rates among all the providers would help maintain and 
possibly increase our Community Health Center Network government funding for our low-
income clinic at FQHC. It would improve health outcomes for our patients and provider 
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Appendix E: Gap Analysis 
Gap Analysis 
Desired Situation Current Situation Action Plan  
Optimize the breast cancer 
mammogram screening 
process to improve overall 
breast health for women at 
FQHC clinics.  
 





screening starting at 
age 50 for all women, 
however, evidence 
suggests other options 
available. 
-Perform literature review on current 
guidelines and best available 
evidence 
-Create Screening Mammogram 
Initiation Protocol (SMIP) 
-Present project proposal to DNP 
chair for approval  
-Present project proposal to Site 
Leader for approval 
-Provide PowerPoint presentation in-
service to FQHC staff  
-Implement SMIP for 6-weeks  
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Appendix F: GANTT Chart 
Project GANTT 










































identify needs of 
FQHC’s clinic for 
potential project 
 






                        













                        
Implement project                          
Collect data and 
analyze 
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Appendix G: Work Breakdown Structure 
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Appendix H: SWOT Analysis 
Strengths Weaknesses 
● Health care professionals have 
expressed a need to better identify, 
address, and counsel on breast cancer 
screening and referral for mammogram 
at the FQHC 
● Increase provider involvement, 
knowledge, and empowerment 
● Increase patient satisfaction scores in 
receiving comprehensive health 
coverage 
● Provide early detection, diagnosis, and 
breast cancer treatment  
● Cost effective with ongoing 
surveillance, prevention, and early 
detection  
 
● No toolkit currently exists that 
incorporates current evidence of best 
practices on breast cancer mammogram 
screening from reputable institutions 
and government agency  
● Resistance from medical assistants 
and/or health care providers that there is 
too little time or not as high of a priority 
to implement during visit  
● Lack of opportunity to use breast cancer 
mammogram algorithm within time 
frame of project  
● The FQHC already follows the 
USPSTF’s grade “A” and “B” 
guidelines for breast cancer screening  
 
Opportunities Threats 
● Increase quality of care and optimize 
breast health outcomes with female 
patients  
● Meets Healthy People 2020 goals 
towards reducing health disparities, 
cancer related disability and mortality 
● Standardize breast cancer policy and 
procedure screening in primary care  
● Decrease morbidity and mortality rates 
especially among a high-risk population  
● Raises awareness and promotes early 
detection, diagnosis, and treatment  
 
● Competing institutions and government 
agency’s recommend varying guidelines 
on initial screening, frequency, and 
discontinuation of mammograms  
● Cultural/language barriers  
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Appendix I: Budget    
Description Calculations Total Cost 
Project Manager time 
 
($67.70/hour x 135 hours = $9,140.60)1 $0  
(DNP student Project) 
Provider time  
(Includes time for 
presentation, pre/post 
surveys, and utilizing 
toolkit) 




Medical Assistant time  
 
($23.25/hour x 3 hours x 6 medical 
assistants = $418.50)4 
$418.50 
Printed Material 
(handouts and toolkit) 
$70 $70 
Food for in-service $40 $40 
Space Rental $0 $0 
Equipment $0 $0 
        Total Budget  $1,887.19 
1. Glassdoor. (2019a). Registered nurse salaries in San Francisco, California area. https://www.glassdoor.com/Salaries/san-
francisco-registered-nurse-salary-SRCH_IL.0,13_IM759_KO14,30.htm 
2. Glassdoor. (2019c). Family Nurse Practitioner salaries in San Francisco, California area. Retrieved from 
https://www.glassdoor.com/Salaries/san-francisco-family-nurse-practitioner-salary-SRCH_IL.0,13_IM759_KO14,39.htm 




Burden of Breast Cancer Disease to the United States Healthcare System 
2010 Cost Estimate for all Cancers  $124.5 billion 
2010 Cost Estimate for Breast Cancer $16.5 billion  
2018 Projected New Breast Cancer Diagnosis 266,120 (30%- Leading) 
2018 Projected Breast Cancer Deaths  40,920 (14% - Second highest) 
2010-2014 Breast Cancer Incidence in California State 120.7 per 100,000 
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Estimated Cost of Breast Health for an Uninsured Female Patient 
Average cost of mammogram per patient $102 
Average total cost of breast cancer treatment per patient $100,000 
 






ACR (if discontinued at age 75) $3,570 
 
ACCS (if discontinued at age 75 annually) 
(if discontinued at age 75 and started biennially after 55) 
$3,570 
$2,550 
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Appendix J: Communication Matrix  
Information Audience Time Methods of Communication 










Project modifications DNP Chair 
DNP Student 
As needed Email 
In-person 
Phone 




As needed Email 
In-person 
Phone 
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Initial Screen at age 40*2
-Per ACOG1 (but can delay first mammogram up to 50 years), ACR2, & NCCN3
-ACS4 Individualized (Qualified recommendation)
-USPSTF5 Individualized (Grade: C Selectively Recommend)
Review Non-Modifiable Risk Factors for Breast Cancer6
-Personal or family (parent, sibling, and/or child) history of breast cancer
-Previous breast biopsy
-History of radiation therapy to the chest
-Known or suspected BRCA mutation 
-Early onset of menses between ages 7-11










and ACS4 if 
starting
Biennial
Until age 50 if 
patient desires
No
-Document decline with reason
-Document counseling/assessment
Rescreen at age 45
-Per ACS4 (Strong recommendation)





-Per ACS4 until age 54, after 
55 patient-provider 
discussion until life 








-Document decline with reason
-Document counseling/assessment
Rescreen at age 50








-Per ACOG1 until 75, anything beyond patient-provider 
discussion
-Per ACR2 until life expectancy <5-7 years or if no further 
intervention planned regardless of imaging results
-Per NCCN3 until life expectancy limited and no further 
intervention planned regardless of imaging results 
-Per ACS4 until age 54, after 55 patient-provider 
discussion until life expectancy <10 years 
Biennial
-Per USPSTF5 until age 74
-Per ACS4 starting at age 
55 every 1-2 years until life 
expectenacy <10 years
No
-Document decline with reason
-Revisit  topic yearly at well-
woman  annual visit
*At anytime, if patient 
has a first  degree 
relative with positive 
breast cancer history 
initiate mammograms 
10 years from 
diagnosis
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Adapted from:  
 
1. American College of Obstetrics and Gynecologists (ACOG) 
The American College of Obstetricians and Gynecologists. (2017). ACOG practice bulletin: 





2. American College of Radiology (ACR) 
Lee, C. H., Dershaw, D. D., Kopans, D., Evans, P., Monsees, B., Monticciolo, D., … Burhenne, 
L. W. (2010). Breast cancer screening with imaging: Recommendations from the society of 
breast imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and 
other technologies for the detection of clinically occult breast cancer. Journal of the American 
College of Radiology, 7(1), 18-27. doi:10.1016/j.jacr.2009.09.022 
 
Monticciolo, D. L., Newell, M. S., Hendrick, R. E., Helvie, M. A., Moy, L., Monsees, B., . . . 
Sickles, E. A. (2017). Breast cancer screening for average-risk women: Recommendations from 
the ACR commission on breast imaging. Journal of the American College of Radiology, 14(9), 
1137-1143. doi:10.1016/j.jacr.2017.06.001 
 
3. National Comprehensive Cancer Network (NCCN) 
Bevers, T. B., Helvie, M., Bonaccio, E., Calhoun, K. E., Daly, M. B., Farrar, W. B., . . . Kumar, 
R. (2018). Breast cancer screening and diagnosis, version 3.2018, NCCN clinical practice 
guidelines in oncology. Journal of the National Comprehensive Cancer Network : 
JNCCN, 16(11), 1362-1389. doi:10.6004/jnccn.2018.0083 
 
4. American Cancer Society (ACS)  
Oeffinger, K. C., Fontham, E. T. H., Etzioni, R., Herzig, A., Michaelson, J. S., Shih, Y. T., . . . 
Wender, R. (2015). Breast cancer screening for women at average risk: 2015 guideline update 
from the American cancer society. Jama, 314(15), 1599-1614. doi:10.1001/jama.2015.12783 
 
5. United States Preventive Services Task Force (USPSTF)  
Siu, A. L. (2016). Screening for breast cancer: U.S. preventive services task force 
recommendation statement. Annals of Internal Medicine, 164(4), 279. doi:10.7326/M15-2886 
 
6. National Institute of Health: National Cancer Institute. (n.d.). The breast cancer risk 
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Breast Cancer Screening Guidelines 
Group Age to Initiate 
Mammograms 
Frequency (years) Age to Discontinue 
Mammograms 
ACOG1 40* 
No later than 50  
1-2* 75, anything beyond is 
provider-patient discussion 
ACR2 40 1 Life expectancy <5-7 years 
or if no further intervention 







1: ages 40-44 if starting 
(Qualified Recommendation) 
 
1: ages 45-54 
(Qualified Recommendation) 
 
1-2: age >55 (Qualified 
Recommendation) 
Life expectancy <10 years 
(Qualified 
Recommendation) 
NCCN4 40 1 Limited life expectancy 
and no further intervention 
planned regardless of 
imaging results  
USPSTF5 40-49 




(Grade B: Recommend) 
2 
(Grade B: Recommend) 
74 
(Grade B: Recommend) 
Adapted from:  
1. American College of Obstetrics and Gynecologists (ACOG) 
The American College of Obstetricians and Gynecologists. (2017). ACOG practice bulletin: Clinical management 




2. American College of Radiology (ACR) 
Lee, C. H., Dershaw, D. D., Kopans, D., Evans, P., Monsees, B., Monticciolo, D., … Burhenne, L. W. (2010 ). 
Breast cancer screening with imaging: Recommendations from the society of breast imaging and the ACR on the use 
of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast 
cancer. Journal of the American College of Radiology, 7(1), 18-27. doi:10.1016/j.jacr.2009.09.022 
 
Monticciolo, D. L., Newell, M. S., Hendrick, R. E., Helvie, M. A., Moy, L., Monsees, B., . . . Sickles, E. A. (2017). 
Breast cancer screening for average-risk women: Recommendations from the ACR commission on breast 
imaging. Journal of the American College of Radiology, 14(9), 1137-1143. doi:10.1016/j.jacr.2017.06.001 
 
3. American Cancer Society (ACS)  
Oeffinger, K. C., Fontham, E. T. H., Etzioni, R., Herzig, A., Michaelson, J. S., Sh ih, Y. T., . . . Wender, R. (2015). 
Breast cancer screening for women at average risk: 2015 guideline update from the American cancer 
society. Jama, 314(15), 1599-1614. doi:10.1001/jama.2015.12783 




4. National Comprehensive Cancer Network (NCCN) 
Bevers, T. B., Helvie, M., Bonaccio, E., Calhoun, K. E., Daly, M. B., Farrar, W. B., . . . Kumar, R. (2018). Breast 
cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology.  Journal of the 
National Comprehensive Cancer Network : JNCCN, 16(11), 1362-1389. doi:10.6004/jnccn.2018.0083 
 
5. United States Preventive Services Task Force (USPSTF)  
Siu, A. L. (2016). Screening for breast cancer: U.S. preventive services task force recommendation 
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Breast Cancer Screening Pre Knowledge -Survey  
 
1. How well do you understand current breast cancer screening protocol practiced at the 
Federally Qualified Health Center for average risk female patient’s? 
  
More than I would like  About right    Less than I would like  
       
 
2. How well do you understand the current breast cancer screening protocol practiced at 
the Federally Qualified Health Center for high risk female patient’s? 
 
More than I would like  About right    Less than I would like  
 
 
3. How well informed are you regarding the various guidelines for screening mammograms 
(ACOG, ACR, ACS, NCCN, USPSTF)?  
 
Very well informed  Somewhat well informed Not at all well informed 
 
 
4. How important is it to you to counsel patients about mammogram screening guidelines 
to select individualized patient screening goals based on risk factors?  
 
Very important  Somewhat important  Not at all important 
 
 
5. How likely are you to implement an individualized screening protocol based on risk 
factors at this time? 
 
Very likely   Somewhat likely  Not at all likely 
 
 
















Breast Cancer Screening Post Knowledge -Survey  
 
1. How well do you understand current breast cancer screening protocol practiced at the 
Federally Qualified Health Center for average risk female patient’s? 
  
More than I would like  About right    Less than I would like  
       
 
2. How well do you understand the current breast cancer screening protocol practiced at 
the Federally Qualified Health Center for high risk female patient’s? 
 
More than I would like  About right    Less than I would like  
 
 
3. How well informed are you regarding the various guidelines for screening mammograms 
(ACOG, ACR, ACS, NCCN, USPSTF)?  
 
Very well informed  Somewhat well informed Not at all well informed 
 
 
4. How important is it to you to counsel patients about mammogram screening guidelines 
to select individualized patient screening goals based on risk factors?  
 
Very important  Somewhat important  Not at all important 
 
 
5. How likely are you to implement an individualized screening protocol based on risk 
factors at this time? 
 
Very likely   Somewhat likely  Not at all likely 
 
 

















Breast Cancer Screening Post Implementation Evaluation  
 
 
1. How comfortable did you feel using the Screening Mammogram Initiation Protocol? 
 




2. How feasible has it been to incorporate during a women’s annual exam?  
 




3. As a provider, using the SMIP tool, were you more engaged in making breast cancer 
screening decisions with your patients? 
 
Yes    Somewhat   Not at all 
 
 
4. As a provider do you see the value in initiating the SMIP protocol? 
 
Yes    Somewhat   Not at all 
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Appendix N: Survey Results  
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Q1: How well do you understand current breast cancer screening 
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Q2: How well do you understand the current breast cancer 
screening protocol practiced at the FQHC for high risk female 
patient’s?
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Q3: How well informed are you regarding the various guidelines 
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Very important
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Q4: How important is it to you to counsel patients about 
mammogram screening guidelines to select individualized patient 
screening goals based on risk factors?  
Post Pre





Feedback Post-Education  
"Great work, I feel well informed after your lecture" 
"Thanks :)" 
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Very likely
Somewhat likely
Not at all likely
Q5: How likely are you to implement an individualized screening 












Very comfortable Somewhat comfortable Not at all comfortable
Q1: How comfortable did you feel using the 
Screening Mammogram Initiation Protocol?

















Very feasible Somewhat feasible Not at all feasible
Q2: How feasible has it been to incorporate 








Yes Somewhat Not at all
Q3: As a provider, using the SMIP tool, were you 
more engaged in making breast cancer screening 
decisions with your patients?





Feedback Post-Implementation  
"I love laminated patient education tools!" 
"Great job! Go dons!" 
"Not sure if I'm really using this protocol, I use the USPSTF recommendations." 




































Yes Somewhat Not at all
Q4: As a provider do you see the value in 
initiating the SMIP protocol?
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Appendix O: I2I Tracking Results  
 
9/10/17-9/10/18 
Age Number of eligible 
participants 
Number referred by 
provider 
Percent Screened  
(Referred/Eligible)  
40-49 1334 863 64% 
50-59 841 617 73% 
 
Project Implementation: 2/6/19-4/10/19 (9 weeks)  
Age Number of eligible 
participants 
Number referred by 
provider 
Percent Screened  
(Referred/Eligible) 
40-49 842 609 72% 
























Women Ages 50-59 Referred for Mammography
